Assessment of Endometrial Changes in Postmenopausal Women With Breast Cancer in Adjuvant Treatment With Anastrozole.
Observational
Time Perspective: Prospective
Global incidence of endometrial changes during the adjuvant treatment with Anastrozole
From inclusion to treatment end(5 years duration) measurements will be taken annually, with a further assessment 12 months after end of treatment.
No
Rosana Cajal, MD
Study Director
AstraZeneca Spain
Spain: Spanish Agency of Medicines
AST-ANA-2004-01
NCT00623519
June 2004
February 2009
Name | Location |
---|